Robert Duggan - Pulse Biosciences Executive CoChairman
| PLSE Stock | USD 16.99 0.14 0.82% |
Chairman
Robert Duggan is Executive CoChairman of Pulse Biosciences
| Age | 81 |
| Phone | 510 906 4600 |
| Web | https://www.pulsebiosciences.com |
Robert Duggan Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Duggan against Pulse Biosciences stock is an integral part of due diligence when investing in Pulse Biosciences. Robert Duggan insider activity provides valuable insight into whether Pulse Biosciences is net buyers or sellers over its current business cycle. Note, Pulse Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Pulse Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Duggan a day ago Acquisition by Robert Duggan of 34510 shares of Pulse Biosciences at 11.0 subject to Rule 16b-3 | ||
Robert Duggan over two months ago Disposition of 24656 shares by Robert Duggan of Pulse Biosciences at 11.0 subject to Rule 16b-3 | ||
Robert Duggan over three months ago Acquisition by Robert Duggan of 55256 shares of Pulse Biosciences at 17.18 subject to Rule 16b-3 | ||
Robert Duggan over three months ago Acquisition by Robert Duggan of 6054 shares of Pulse Biosciences at 16.74 subject to Rule 16b-3 |
Pulse Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3815) % which means that it has lost $0.3815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7028) %, meaning that it created substantial loss on money invested by shareholders. Pulse Biosciences' management efficiency ratios could be used to measure how well Pulse Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | CHAIRMAN Age | ||
| Ronald Gelbman | Haemonetics | 70 | |
| George LeMaitre | LeMaitre Vascular | 60 | |
| Ellen Zane | Haemonetics | 69 | |
| Kevin Cornwell | Utah Medical Products | 78 | |
| Neal CFA | Milestone Scientific | 81 | |
| Richard Meelia | Haemonetics | 71 | |
| Vivek Jain | ICU Medical | 53 | |
Management Performance
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.38 |
Pulse Biosciences Leadership Team
Elected by the shareholders, the Pulse Biosciences' board of directors comprises two types of representatives: Pulse Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pulse. The board's role is to monitor Pulse Biosciences' management team and ensure that shareholders' interests are well served. Pulse Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pulse Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patty Perla, Vice Resources | ||
| Paul LaViolette, CEO and Presidentident | ||
| Robert Duggan, Executive CoChairman | ||
| Sandra Gardiner, CFO Admin | ||
| JD Esq, General Secretary | ||
| Gansevoort MD, Chief Officer | ||
| Niv MD, Chief Surgery | ||
| Richard Nuccitelli, Chief Officer | ||
| Darrin Uecker, Principal CTO | ||
| Kevin Danahy, President CEO | ||
| Mitchell Levinson, Chief Director | ||
| Holly JD, VP Strategy | ||
| Burke Barrett, CEO President | ||
| David Danitz, Senior Engineering | ||
| Edison Manuel, Vice Operations | ||
| Jon Skinner, Chief Officer |
Pulse Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pulse Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 983.11 M | ||||
| Shares Outstanding | 61.52 M | ||||
| Shares Owned By Insiders | 71.93 % | ||||
| Shares Owned By Institutions | 9.31 % | ||||
| Number Of Shares Shorted | 2.2 M | ||||
| Price To Earning | (22.54) X | ||||
| Price To Book | 13.32 X | ||||
| Price To Sales | 60.23 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pulse Biosciences is a strong investment it is important to analyze Pulse Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulse Biosciences' future performance. For an informed investment choice regarding Pulse Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulse Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Pulse Stock refer to our How to Trade Pulse Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulse Biosciences. If investors know Pulse will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulse Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pulse Biosciences is measured differently than its book value, which is the value of Pulse that is recorded on the company's balance sheet. Investors also form their own opinion of Pulse Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pulse Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulse Biosciences' market value can be influenced by many factors that don't directly affect Pulse Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulse Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulse Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulse Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.